2. Academic Validation
  3. Dexmedetomidine attenuates postoperative delirium by activating Nrf2 to reduce oxidative stress and blood-brain barrier disruption

Dexmedetomidine attenuates postoperative delirium by activating Nrf2 to reduce oxidative stress and blood-brain barrier disruption

  • Brain Res Bull. 2025 Aug 24:230:111523. doi: 10.1016/j.brainresbull.2025.111523.
Tengchen Feng 1,  Jie Yao 2,  Yanlin Chen 3,  Jiayi Wang 3,  Ying Zhu 3,  Zhiming Lan 3,  Xuhua Huo 4,  Yeming Wang 3,  Jingui Gao 5
Affiliations

Affiliations

  • 1 Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China; Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China.
  • 2 Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China; Hebei Key Laboratory of Systems Biology and Gene Regulation, Central Laboratory，The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China.
  • 3 Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China.
  • 4 Office of Organ Procurement Organization, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
  • 5 Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China. Electronic address: 26501219@hebmu.edu.cn.
PMID: 40858194 DOI: 10.1016/j.brainresbull.2025.111523
Abstract

Background: Postoperative delirium (POD), characterized by cognitive dysfunction, is a prevalent and severe complication following surgery. The blood-brain barrier (BBB) is crucial in maintaining central nervous system (CNS) homeostasis, and its disruption is associated with POD. Dexmedetomidine (DEX), an α2-adrenergic receptor agonist, potentially reduces POD incidence by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which regulates antioxidant responses and alleviates BBB damage.

Methods: This study used transcriptomic analysis to identify differentially expressed genes in patients with POD and explored the therapeutic targets of DEX. In vitro experiments using HCMEC/D3 cells and an in vivo mouse model of POD were conducted to assess the effects of DEX on BBB integrity and neuroinflammation. Western blotting, flow cytometry, and ELISA were used to evaluate protein expression, Apoptosis, and cytokine levels, respectively. Behavioral tests (open-field and Y-maze tests) were performed to assess cognitive function in mice.

Results: Bioinformatics analysis revealed Nrf2 as a key target of DEX. DEX treatment significantly increased Nrf2 expression and alleviated oxidative stress and neuroinflammation in HCMEC/D3 cells. In the POD mouse model, DEX improved cognitive function, evidenced by enhanced performance in behavioral tests. DEX also upregulated Nrf2 expression in the mouse brain tissue and reduced serum inflammatory. Furthermore, DEX preserved BBB integrity by upregulating tight junction proteins, which was reversed by the Nrf2 inhibitor, ML385.

Conclusions: DEX ameliorates POD by activating Nrf2, thereby reducing oxidative stress and inflammation, and maintaining BBB integrity. These findings suggest DEX is a potential therapeutic agent for POD, highlighting the Nrf2 pathway as a novel target for treatment strategies.

Keywords

Blood-brain barrier; Dexmedetomidine; Nrf2; Oxidative Stress; Postoperative delirium.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z